Trial Profile
A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 13 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2022 Primary endpoint (Durable Response Rate (DRR) Using Modified World Health Organization (WHO) Response Criteria) has been met, according to Results published in the Cancer Science.
- 01 Aug 2022 Results published in the Cancer Science